Fig. 5

Ricolinostat enhanced proliferation of CD34⁺CD41a⁺ cells. A Schematic diagram illustrating CD34⁺CD41a⁺ cells sorted from expanded HSPCs and then treated with Ricolinostat for 7 days. B CFSE time series obtained from CD34⁺CD41a⁺ populations. All cells obtained from the first stage were labeled with CFSE on the first day of the second stage (day 0). The CFSE fluorescence intensity of CD34⁺CD41a⁺ cells was detected by flow cytometry for 7 consecutive days. C Flow cytometry analysis of CD34, CD41a, and CD61 expression in Ricolinostat-treated CD34⁺CD41a⁺ cells. D Percentage of CD34⁺CD41a⁺ cells in Ricolinostat-treated CD34⁺CD41a⁺ cells. E Absolute counts of CD34⁺CD41a⁺ cells were calculated and normalized to the initial sorted CD34⁺CD41a⁺ cells. F Percentage of CD41a⁺CD61⁺ cells in Ricolinostat-treated CD34⁺CD41a⁺ cells. G Absolute counts of CD41a⁺CD61⁺ cells were calculated and normalized to the initial sorted CD34⁺CD41a⁺ cells. H qRT-PCR analysis of some MkP-related genes in Ricolinostat-treated and -untreated CD34⁺CD41a⁺ cells. Results are expressed as the mean ± SEM from three independent experiments. Unpaired Student’s t-test, *p < 0.05; **p < 0.01